Dermoscopy Augmented Histology Trial, a Randomized Controlled Trial

Trial statusNot yet recruiting
Trial phaseNot applicable
Trial typeInterventional
Biological sexAll
AgeNot listed
SponsorHerlev Hospital

About this trial

Pathologists provide the current gold standard in skin lesion diagnostics, most often primarily based on the interpretation of histological slides. Still, it has been suggested that pathologists' diagnostic accuracy and confidence could be improved if they gained access to additional clinical information and in-vivo clinical and dermoscopic images of melanocytic tumors. This study examines the effect of digital training for pathologists in interpreting dermoscopic and clinical skin tumor images.

This study aims to evaluate the impact of dermoscopy training on pathologists' assessment of melanoma-suspected skin lesions.

Data collection of DAHT cases: Department of plastic surgery, Herlev hospital, year 2020-2021,

DAHT platform: Made in 2021-2023 by Melatech,

Consensus agreement: Four dermatopathologists assess all DAHT cases, year 2023-2024

Enrollment of pathologists: Randomization and assessment DAHT cases, year 2026.

Eligibility criteria

Qualifiers

Pathologists are required to evaluate melanocytic lesions routinely

Doctors must be registered authorized health personnel

Access to a smartphone/tablet/computer with internet

Disqualifiers

None

Trial design

Treatments tested in this trial

  • DermLoop Learn

Treatment groups

258 Participants
are divided into 2 treatment groups

Locations

This trial has no locations

Sponsors and collaborators